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GLOSSARY OF TERMINOLOGY

Acute coronary occlusion: The partial or complete obstruction of blood flow in a
coronary artery.
Afterload: Resistance to ventricular ejection: measured clinically with aortic blood
pressure and calculation of systemic vascular resistance.
Angina: Chest pain or discomfort that occurs when an area of heart muscle does
not get enough oxygen-rich blood.
Apoptosis: Occurrence of internucleosomal fragmentation of genomic DNA
associated with a sealed plasma membrane.
Bradyarrhythmias: Slow heart rate, an arrhythmia caused by failure of impulse
formation or by failure of impulse conduction.
Cardiac arrest: The sudden complete loss of cardiac output and therefore blood
pressure.
Cardiac Output: Cardiac output is the volume of blood being pumped by the
heart, in particular by a ventricle in a minute. Cardiac output is equal to the stroke
volume multiplied by the heart rate .
Cardiac arrhythmia (also dysrhythmia): Abnormal electrical activity in the heart.
The heartbeat may be fast or slow, and may be regular or irregular.
Coronary Artery Bypass Graft Surgery: Colloquially heart bypass or bypass
surgery is a surgical procedure where arteries or veins from elsewhere in the
patient's body are grafted to the coronary arteries to bypass atherosclerotic
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narrowing and improve the blood supply to the coronary circulation supplying the
myocardium.
Cost-effectiveness ratios: A ratio of the change in costs of a therapeutic
intervention to the change in effects of the intervention.
Diastolic arterial pressure: The lowest pressure (at the resting phase of the cardiac
cycle). Typical values for a resting, healthy adult human are approximately
120mmHg systolic and 80mmHg diastolic with large individual variations.
End-diastolic pressure: The pressure in the ventricles at the end of diastole,
usually measured in the left ventricle as an approximation of the end-diastolic
volume, or preload.
End-diastolic volume: The volume of blood in a ventricle at the end of filling
(diastole). Because greater end diastolic volumes cause greater distention of the
ventricle, end diastolic volume is often used synonymously with preload.
Fibrin: Insoluble protein that is produced in response to bleeding and is the major
component of the blood clot.
Free radicals: Any atomic or molecular species capable of independent existence
that contains one or more unpaired electrons in one of its molecular orbitals.
Ischemia: Oxygen deprivation accompanied by inadequate removal of metabolites
due to reduced perfusion. Prolonged ischemia results in tissue damage and death
because of a lack of oxygen and nutrients.
Hemostasis: Refers to the physiologic process whereby bleeding is halted, thus
protecting the integrity of the vascular system after tissue injury.
Ischemia reperfusion: The restoration of blood flow to an area that had previously
experienced deficient blood flow.
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Ischemic heart disease: A condition in which there is an inadequate supply of
blood and oxygen to a portion of the myocardium; it typically occurs when there is
an imbalance between myocardial oxygen supply and demand.
Ischemic reperfusion injury: Accelerated and additional myocardial injury
beyond that generated by ischemia alone. It includes hastening of the necrotic
process of irreversibly injured myocytes, cell swelling, the no-reflow phenomenon,
hemorrhagic myocardial infarction, the calcium and oxygen paradox, the
production of oxygen-derive free radicals which may damage ischemic myocytes,
and the prolonged postischemic depression of ventricular function and
electrophysiologic changes which in turn can cause arrhythmias.
Ischemic preconditioning: A technique in which tissue is rendered resistant to the
deleterious effects of prolonged ischemia and reperfusion by prior exposure to
brief, repeated periods of vascular occlusion.
Myocardial infarction (MI): A loss of cardiac myocytes (necrosis) caused by
prolonged ischemia.
Myocardial stunning: The mechanical dysfunction that persists after reperfusion,
despite the absence of irreversible damage and restoration of normal coronary flow.
Necrosis: The ultimate form of cell death and defined as accidental collapse of
cellular homeostasis, compartmentalisation and cell membrane integrity with the
release of cytosolic material and with random nuclear DNA fragmentation.
Nutritional preconditioning: Inducing preconditioning by nutritional means.
(n−3) fatty acids: n−3 fatty acids (popularly referred to as omega-3 fatty acids or
ω−3 fatty acids) are a family of unsaturated fatty acids that have in common their
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first carbon–carbon double bond as the third bond from the methyl end of the fatty
acid.
(n−6) fatty acids: n−6 fatty acids (popularly referred to as omega-6 fatty acids or
ω−6 fatty acids) are a family of unsaturated fatty acids which have in common their
first carbon–carbon double bond as the sixth bond from the methyl end of the fatty
acid.
Oncosis: Early plasma membrane rupture and disruption of cellular organelles,
including mitochondria.
Percutaneous transluminal coronary angioplasty: Commonly known as
coronary angioplasty or simply angioplasty, a form of catheter-based therapy as an
alternative to bypass surgery is to treat the stenotic coronary arteries of the heart
found in coronary heart disease. Angioplasty is less invasive than coronary artery
bypass surgery.
Plasminogen: The inactive precursor of plasmin, a potent serine protease involved
in the dissolution of fibrin blood clots.
Primary prevention: Can include prevention of atherosclerosis, acute coronary
occlusion myocardial infarction and sudden cardiac death.
Pharmacological preconditioning: Inducing preconditioning by pharmacological
means.
Preload: The pressure stretching the ventricular wall of the heart after passive
filling and atrial contraction. Preload is theoretically most accurately described as
the initial stretching of a single cardiac myocyte prior to contraction.
Secondary prevention: Prevention of fatal arrhythmias or new ischemic episodes
in those who have had a prior heart attack.
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Stroke volume: The volume of blood pumped out of one ventricle of the heart in a
single beat.
Stroke work: The work done by the ventricle to eject a volume of blood (i.e.,
stroke volume) into the aorta.
Stunning: Viable myocardium, which is not contracting properly but is not acutely
ischemic.
Systolic arterial pressure: The peak pressure in the arteries, which occurs near the
beginning of the cardiac cycle.
Sudden cardiac death: Natural death from cardiac causes, heralded by abrupt loss
of consciousness within one hour of the onset of acute symptoms; preexisting heart
symptoms may have been known to be present, but the time and mode of death are
unexpected.
Thrombus or blood clot: The final product of the blood coagulation step in
hemostasis.
Thrombosis: The formation of a clot or thrombus inside a blood vessel, which
obstructs the flow of blood through the circulatory system.
Ventricular tachycardia: Three or more consecutive ventricular premature beats.
If persistent, causes loss of blood pressure and death.
Ventricular fibrillation: A rapid, chaotic, and asynchronous contraction of the left
ventricle.
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ABSTRACT

Cardiovascular disease now ranks as the leading cause of death, resulting in one
third of all deaths in the world, among which ischemic heart disease is projected to
be the number one cause of death globally. It has been long suggested that (n-3)
polyunsaturated fatty acids provide cardiovascular protection, with regular intake of
fish or fish oil associated with reduced mortality from heart diseases in both clinical
trials and epidemiological studies. One major observation in these studies is that
fish oil has been found to reduce mortality during or following ischemic events.
While ischemia damages the heart, short bursts of ischemia paradoxically protect
the heart from the damaging effects of more prolonged ischemia. This powerful
cardioprotective phenomenon is termed ischemic preconditioning. The protective
influences of ischemic preconditioning include reduction of infarct size, prevention
of life-threatening arrhythmias in ischemia and reperfusion, reduced myocardial
oxygen demand, and improved recovery of post-ischemic cardiac pumping
function. However, the promise of ischemic preconditioning has not yet been
realized in bench to bedside application. The characteristics of cardioprotection
afforded by feeding (n-3) PUFA suggests preconditioning-like effects, related to
incorporation of (n-3) PUFA into heart membranes. However, the long chain highly
unsaturated (n-3) PUFA in the membranes are highly susceptible to peroxidation,
perhaps making cardiac membranes more susceptible to free radical generation and
cellular damage. While free radicals are thought to be involved in the damaging
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effects of ischemia and reperfusion, they also play a role in protective mechanisms
of ischemic preconditioning.

This study evaluated the effects of fish oil on (n-3) PUFA incorporation into
myocardial membrane and examined the susceptibility to oxidative damage and
myocardial injury in terms of infarct size and postischemic cardiac function.
Further, it compared dietary fish oil with ischemic preconditioning and assessed
their interaction for effects on heart function and injury during myocardial ischemia
and reperfusion. It tested the hypothesis that the susceptibility to peroxidation may
provide an ever-present preconditioning stimulus that protects the heart against the
damaging effects of a major ischemia reperfusion insult.

Male Wistar rats were fed one of three fully fabricated diets containing 10% fat by
weight varying only in the types of fat. The (n-3) PUFA diet contained 7% fish oil
+ 3% olive oil; The (n-6) PUFA diet contained 5% sunflower seed oil + 5% olive
oil; The saturated fatty acid (SF) diet contained 7% saturated fat-rich beef tallow +
3% olive oil. Heart function was examined after six weeks feeding using
Langendorff-perfused

isolated

isovolumic

heart

preparation.

In

control

experiments, isolated perfused hearts were subjected to 30 minutes regional
ischemia by occluding the left anterior descending coronary artery, then reperfused
for 120 minutes. Ischemic preconditioning consisted of three cycles of five minutes
global ischemia before the 30 minutes regional ischemia and 120 minutes
reperfusion. Heart function was assessed during perfusion by ECG and by
measurement of intraventricular pressure. Infarct size was measured at completion
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of perfusion in control and ischemic preconditioned hearts as a percent of the
ischemic zone at risk. Lipid peroxidation products and antioxidant concentrations
were measured in normoxic heart and in ischemic and non-ischemic regions of
hearts with or without ischemic preconditioning.

Control (n-3) PUFA hearts had significantly lower spontaneous heart rate, coronary
flow, end diastolic pressure, maximum relaxation rate, and fewer ischemic
reperfusion arrhythmias than did (n-6) PUFA hearts or SF hearts. In reperfusion (n3) PUFA hearts maintained greater developed pressure and maximum rate of
relaxation and developed smaller infarcts (10.9±3.6% ischemic zone, n=6) than (n6) PUFA hearts (47.4±2.3%, n=6) or SF hearts (50.3±4.3%, n=6).

Ischemic preconditioning significantly improved heart function and reduced infarct
size in (n-6) PUFA hearts (11.8±5.4%, n=6) and SF hearts (13.1±4.2%, n=6). Heart
function and infarct size did not differ between control and ischemic preconditioned
hearts (9.6±4.2%) with (n-3) PUFA diet. Arrhythmias were significantly reduced
by ischemic preconditioning in (n-6) PUFA hearts or saturated fatty acid hearts
towards levels observed in (n-3) PUFA hearts.

Myocardial membranes showed high incorporation of long chain docosahexaenoic
acid (DHA) (22:6,n-3), predicting increased risk of peroxidation. The concentration
of lipid hydroperoxides and malondialdehyde were higher in normoxic and
nonischemic regions of control (n-3) PUFA hearts than in (n-6) PUFA or SF hearts.
The concentration of the endogenous antioxidant superoxide dismutase was higher
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in normoxic and nonischemic regions of control (n-3) PUFA hearts and was
increased after ischemic preconditioning in saturated fatty acid and (n-6) PUFA
hearts. Both (n-3) PUFA diet and ischemic preconditioning inhibited the ischemiainduced rise in the oxidation products lipid hydroperoxides and malondialdehyde.

This thesis demonstrated that the harmful effects of myocardial ischemia and
reperfusion, such as infarct size, poor relaxation, cardiac arrhythmia and poor
recovery of contractile function were largely curtailed by feeding an (n-3) PUFA
rich diet. The effects of SF and (n-6) PUFA diet on heart function and ischemia
susceptibility were largely indistinguishable, indicating that the effects of fish oil
were specifically related to its (n-3) PUFA content and not due to either a reduction
in saturated fat intake or a non-specific role of polyunsaturated fatty acids. Regular
consumption of dietary fish oil induced sustained changes in membrane fatty acid
composition and produced cardioprotection that appears similar to late ischemic
preconditioning. The continuous presence of (n-3) PUFA in myocardial membranes
suggests that, as reported for late ischemic preconditioning, this is not subject to
desensitization.

Dietary treatment of rats with (n-3) PUFA caused an increase in peroxidation index
suggesting an increase in susceptibility of the membrane to oxidative damage,
which might be expected to enhance ischemic damage. An increase in membrane
lipid peroxidation was indeed observed in fish oil treated rat hearts, however, it was
associated with increased antioxidant activity and reduced lipid oxidation under
stress and instead of causing lasting damage to heart function, beneficial effects on
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arrhythmia, contractile function, and myocardial infarct size were observed. These
protective effects are demonstrated as powerful as ischemic preconditioning.

Therefore, in light of cardioprotective effects of (n-3) PUFA to reduce the
consequences of ischemic events in the human population when a regular part of the
diet, the present thesis demonstrated that (n-3) PUFA induces a form of
preconditioning in the heart, which this thesis has termed, nutritional preconditioning.
The (n-3) PUFA limit ischemic cardiac injury and myocardial infarction and endow
cardioprotection as powerful as ischemic preconditioning under these experimental
conditions. Nutritional preconditioning by membrane incorporation of (n-3) PUFA
may underpin the low cardiovascular morbidity and mortality associated with regular
fish and fish oil consumption.
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